Novavax (NASDAQ: NVAX) investors are looking at a share price decline of more than 90% over the past 12 months, and the shares are now trading close to their 52-week low. Though it successfully commercialized its Nuvaxovid jab in a slew of countries for primary series COVID-19 vaccinations, and also for booster vaccinations, the biotech is struggling to find a profitable future amid declining demand and persistent problems with its manufacturing operations.
The risk of this company failing to make a turnaround appears high. But savvy investors recognize that there's often an opportunity for significant returns on investment when the general market sentiment about a business is poorer than is warranted.
So is Novavax stock a buy now, during what appears to be the winter of its discontent, or would investors be better served to avoid it and invest in more reliable businesses? The better choice is the latter one, and it isn't a contest. Here's why.
Source Fool.com